State of Arkansas *As Engrossed: H3/17/17*
91st General Assembly **A Bill**
Regular Session, 2017 SENATE BILL 361

By: Senator Flippo

For An Act To Be Entitled

AN ACT TO CREATE AN EXEMPTION FROM THE LAWS REGARDING THE PRACTICE OF PHARMACY FOR DIALYSATE OR DEVICES NECESSARY FOR HOME PERITONEAL KIDNEY DIALYSIS IN CERTAIN SITUATIONS; AND FOR OTHER PURPOSES.

Subtitle

TO CREATE AN EXEMPTION FROM THE LAWS REGARDING THE PRACTICE OF PHARMACY FOR DIALYSATE OR DEVICES NECESSARY FOR HOME PERITONEAL KIDNEY DIALYSIS IN CERTAIN SITUATIONS.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:

SECTION 1. Arkansas Code Title 17, Chapter 92, Subchapter 1, is amended to add an additional section to read as follows:

17-92-115. Exemption for home peritoneal kidney dialysis.

(a) The provisions of §§ 17-92-101, 17-92-103, 17-92-105, 17-92-205, 17-92-206, 17-92-303, 17-92-401, 17-92-402, 17-92-404, 17-92-405, 17-92-409, 17-92-410, 17-92-411, and 17-92-902 do not apply to the sale or distribution of dialysate or devices necessary to perform home peritoneal kidney dialysis to patients with end stage renal disease if:

(1) The dialysate composed of dextrose or icodextrin or devices are:

(A) Approved or cleared by the United States Food and Drug Administration as required by federal law;

(B) Lawfully held by a manufacturer or a third-party

logistics provider of the manufacturer that is properly registered with the Arkansas State Board of Pharmacy as a wholesale distributor or medical device provider;

(C) Held and delivered in original, sealed packaging from the manufacturing facility; and

(D) Delivered only by the manufacturer or a third-party logistics provider of the manufacturer and only upon receipt of a physician's *order by a licensed pharmacy and the transmittal of an order from a licensed pharmacy to the manufacturer or a third party logistics provider of the manufacturer; and*

(2) The manufacturer or a third-party logistics provider of the manufacturer delivers the dialysate or devices directly to:

(A) A patient with end stage renal disease or a designee for the self-administration of the dialysis therapy; or

(B) A healthcare provider or institution for administration or delivery of the dialysis therapy to a patient with end stage renal disease.

(b)(1) The board shall retain oversight of all other drugs for home peritoneal kidney dialysis with the exception of dialysate as described in subdivision (a)(1) of this section.

(2) All records of sales and distribution of dialysate to patients under this section shall be retained according to state law and rule of the board.

/s/Flippo

APPROVED: 03/28/2017